来自官方财务报表的收入、利润与现金流历史。
Divi's Laboratories Limited engages in the manufacture and sale of generic active pharmaceutical ingredients (APIs), intermediates, and nutraceuticals in India, North America, Asia, Europe, and internationally. The company also undertakes custom synthesis contract manufacturing services of APIs and intermediates; and supplies a range of carotenoids, such as astaxanthin, beta-carotene, lycopene, canthaxanthin, apocarotenal, and vitamins used in the food, beverage, dietary supplement, pet food, and feed industries. It also exports its products.
| 利润表 | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 |
|---|---|---|---|---|
| 总收入 | ₹104.8B | ₹93.2B | ₹78.0B | ₹76.7B |
| 毛利 | ₹62.0B | ₹54.5B | ₹45.3B | ₹44.9B |
| 营业利润（EBIT） | ₹29.8B | ₹25.7B | ₹18.3B | ₹20.3B |
| 净利 | ₹25.7B | ₹21.9B | ₹16.0B | ₹18.2B |
来源：公司公开报告（SEC）。在依赖任何数字前请核对 SEC EDGAR。
资产负债表、现金流、季度数据与完整财务比率见 DIVISLAB 交互式查看器。 /companies/us/DIVISLAB
本网站信息仅用于教育与参考，不构成投资建议。不发布目标价或买卖建议。
About TickerBase · Data methodology & sources · Privacy · Terms